Edinburgh Postnatal Depression Scale (EPDS): A Comprehensive Guide to This Clinical Screening Tool

The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-report questionnaire designed to screen for symptoms of depression during pregnancy and the postpartum period. Developed in 1987 by psychiatrists John Cox, Jeni Holden, and Ruth Sagovsky at health centers in Edinburgh and Livingston, Scotland, the EPDS was created specifically to address a critical gap in perinatal mental health: the lack of a screening instrument that could distinguish depressive symptoms from the normal physiological experiences of new parenthood.

Traditional depression screening tools — such as the Beck Depression Inventory (BDI) — include items about fatigue, appetite changes, and sleep disturbance. While these are hallmark symptoms of major depressive disorder in the general population, they are also nearly universal experiences during pregnancy and the postpartum period. The EPDS was specifically engineered to avoid these somatic symptoms, focusing instead on the cognitive and emotional dimensions of depression: anhedonia (inability to experience pleasure), anxiety, guilt, sadness, difficulty coping, and self-harm ideation.

Since its publication, the EPDS has become the most widely used perinatal depression screening tool in the world. It has been translated into more than 60 languages and is recommended by major clinical organizations including the American College of Obstetricians and Gynecologists (ACOG), the UK National Institute for Health and Care Excellence (NICE), and the World Health Organization (WHO).

The EPDS measures the severity of depressive symptoms experienced over the past seven days. It is not a diagnostic instrument — it does not confirm or rule out a diagnosis of major depressive disorder, postpartum depression, or any other condition defined in the DSM-5-TR. Rather, it functions as a screening tool that identifies individuals who may benefit from a more thorough clinical evaluation.

The 10 items on the EPDS assess the following symptom domains:

• Anhedonia: Difficulty finding humor in things and inability to look forward to enjoyment (Items 1 and 2)
• Self-blame: Unnecessary feelings of guilt or self-reproach when things go wrong (Item 3)
• Anxiety: Feeling anxious or worried without good reason (Items 4 and 5)
• Fear and panic: Feeling scared or panicky for no clear reason (Item 6)
• Inability to cope: Feeling overwhelmed to the point that things are "piling up" (Item 7)
• Sadness: Feeling sad or miserable (Item 8)
• Crying: Being so unhappy that crying occurs (Item 9)
• Self-harm ideation: Thoughts of harming oneself (Item 10)

Item 10 is particularly significant clinically. Any endorsement of self-harm thoughts — even at the lowest positive level — warrants immediate follow-up regardless of the total score. This single item serves as a critical safety screen embedded within the broader depression assessment.

Notably, while the EPDS was designed primarily to detect depressive symptoms, research has consistently demonstrated that it also captures significant anxiety symptoms. Items 3, 4, and 5 form an anxiety subscale that some clinicians use to assess perinatal anxiety alongside depression. This is clinically important because anxiety disorders are at least as prevalent as depression during the perinatal period, and the two conditions frequently co-occur.

The EPDS was originally developed for use with postpartum women, typically administered at approximately six to eight weeks after delivery. However, its clinical use has expanded considerably since its original publication.

Pregnant individuals: The EPDS is now widely used as an antenatal (prenatal) screening tool. Research supports its validity during pregnancy, and organizations such as ACOG recommend screening at least once during the perinatal period, with many guidelines advocating for screening during each trimester and the postpartum period.

Partners and fathers: A growing body of research supports the use of the EPDS with fathers and non-birthing partners during the perinatal period. Paternal postnatal depression affects an estimated 8–10% of fathers, and the EPDS has demonstrated acceptable validity in male populations, though some researchers have proposed lower cutoff scores (typically 9 or 10 rather than 12 or 13) for men.

Diverse populations: The EPDS has been validated across numerous cultural and linguistic groups. However, cultural factors can influence how individuals interpret and respond to items about emotional experience, self-blame, and especially self-harm. Clinicians should be aware that cutoff scores validated in one population may not perform identically in another.

The tool is appropriate for individuals aged 18 and older. It is not designed for use with adolescents under 18, although some research has explored its applicability in younger perinatal populations with modified interpretation guidelines.

One of the EPDS's greatest strengths is its simplicity of administration. The tool is a self-report questionnaire that most individuals can complete independently in approximately five minutes. It requires no specialized training to administer, though clinical training is essential for interpreting results and determining appropriate follow-up actions.

Administration format: The EPDS can be administered on paper or electronically. Digital administration has become increasingly common in clinical settings, integrated into electronic health record (EHR) systems and patient portals. Research indicates that paper and electronic versions produce equivalent results.

Instructions to the respondent: The individual is asked to select the response that best describes how they have felt during the past 7 days — not just how they feel today. This timeframe is important: it reduces the impact of transient mood fluctuations while remaining sensitive to clinically significant symptom patterns.

Scoring format: Each of the 10 items offers four response options scored from 0 to 3. Some items are reverse-scored, meaning the response order is inverted so that higher scores consistently indicate greater symptom severity. The total score ranges from 0 to 30.

Administration setting: The EPDS is typically administered in obstetric clinics, midwifery practices, pediatric offices (during well-child visits), health visitor consultations, and mental health settings. It can also be used in community health programs and research contexts.

Frequency: There is no single standard for how often the EPDS should be administered. Many clinical guidelines recommend screening at the first prenatal visit, at least once during the third trimester, and at postpartum visits (commonly at 4–6 weeks and again at 3–6 months). Repeated screening is valuable because the onset of perinatal depression can occur at any point from conception through the first year postpartum.

Scoring the EPDS is straightforward. Each item is scored 0, 1, 2, or 3, with higher scores reflecting greater symptom severity. Items 1, 2, and 4 are scored in the standard direction (the first response option scores 0), while items 3, 5, 6, 7, 8, 9, and 10 are reverse-scored (the first response option scores 3). The total score is the sum of all 10 items.

The most commonly cited interpretation thresholds are as follows:

• 0–9: Depression not likely. Scores in this range suggest symptoms within normal limits, though individual items — particularly Item 10 — should still be reviewed.
• 10–12: Possible depression. Scores in this range indicate the presence of depressive symptoms that warrant monitoring and potential reassessment in two to four weeks.
• 13 or higher: Probable depression. Scores at or above this threshold are associated with a high likelihood of a depressive episode and indicate the need for a comprehensive clinical evaluation.

It is important to emphasize that these cutoff scores are not universal. The original validation study by Cox, Holden, and Sagovsky (1987) identified a score of 12/13 as optimal for identifying major depression, with a sensitivity of 86% and specificity of 78%. However, different clinical and research contexts use different thresholds. Some guidelines use a cutoff of 10 for initial screening to maximize sensitivity, accepting a higher rate of false positives in exchange for identifying more individuals who may need help. Other studies have proposed cutoffs ranging from 9 to 13 depending on the population, language version, and clinical purpose.

Critical safety item: Regardless of the total score, any response other than "Never" on Item 10 ("The thought of harming myself has occurred to me") requires immediate clinical follow-up, including a direct conversation about suicidal ideation, intent, plan, and access to means. A score of 1 on this item ("Hardly ever") still represents an endorsement of self-harm thoughts and must not be dismissed.

Clinicians should interpret EPDS scores in the context of the individual's full clinical picture, including medical history, psychosocial stressors, cultural background, and current functioning. A score below the cutoff does not rule out depression, and a score above the cutoff does not confirm it.

The EPDS has one of the most robust evidence bases of any screening instrument in perinatal mental health. Decades of research across dozens of countries have established its psychometric properties.

Sensitivity and specificity: Meta-analyses have found that at a cutoff score of 13, the EPDS demonstrates a pooled sensitivity of approximately 80–85% and a specificity of approximately 75–85% for detecting major depressive disorder in postpartum women when compared against structured diagnostic interviews (the gold standard). These values indicate that the EPDS correctly identifies the majority of individuals with depression while maintaining a reasonable rate of false positives.

Internal consistency: Cronbach's alpha for the EPDS typically ranges from 0.82 to 0.88 across studies, indicating strong internal reliability — the items consistently measure a coherent underlying construct.

Test-retest reliability: Studies have demonstrated adequate test-retest reliability over short intervals (typically one to two weeks), suggesting that scores are reasonably stable when underlying symptoms have not changed.

Convergent validity: EPDS scores correlate strongly with other established measures of depression, including the Beck Depression Inventory, the Patient Health Questionnaire-9 (PHQ-9), and the Hamilton Rating Scale for Depression. These correlations confirm that the EPDS is measuring depressive symptomatology as intended.

Factor structure: Research has identified a two- or three-factor structure underlying the EPDS. Most analyses find distinct factors for depression, anxiety, and anhedonia, which supports the tool's utility in capturing the breadth of perinatal mood disturbance beyond classic depressive symptoms.

Positive predictive value: The positive predictive value (PPV) — the probability that an individual who screens positive actually has depression — varies depending on the prevalence of depression in the population being screened. In populations where perinatal depression prevalence is approximately 10–15%, the PPV at a cutoff of 13 is typically around 50–75%. This means that a significant proportion of positive screens will not meet full diagnostic criteria upon evaluation, underscoring the importance of the EPDS as a screening tool, not a diagnostic one.

Despite its widespread adoption and strong evidence base, the EPDS has meaningful limitations that clinicians and researchers should understand.

• It is a screening tool, not a diagnostic instrument. The EPDS cannot diagnose postpartum depression, major depressive disorder, or any other psychiatric condition. A positive screen must always be followed by a comprehensive clinical assessment. Over-reliance on the score alone, without clinical interview, can lead to both over- and under-identification of depression.
• Cultural and linguistic variability. Although the EPDS has been translated into more than 60 languages, translation does not guarantee equivalent psychometric performance. Concepts like "blaming oneself unnecessarily" or "looking forward with enjoyment" carry different connotations across cultures. Validated cutoff scores in one population may not apply to another.
• Limited assessment of somatic symptoms. The deliberate exclusion of somatic symptoms — the EPDS's design strength — also means it may underdetect depression in individuals whose presentation is predominantly somatic (e.g., psychomotor retardation, significant appetite or weight change).
• Self-report bias. Like all self-report measures, the EPDS is susceptible to response biases. Individuals may underreport symptoms due to stigma, fear of consequences (such as child protective services involvement), social desirability, or poor insight into their own emotional state. On the other hand, some individuals may overreport symptoms.
• Limited scope. The EPDS does not screen for postpartum psychosis, bipolar disorder, post-traumatic stress disorder related to birth trauma, or other perinatal mental health conditions. It is designed to detect depressive and anxious symptomatology specifically.
• Single-point-in-time assessment. A single EPDS administration captures symptoms from one seven-day period. Perinatal depression can develop at any point during the perinatal year, so a negative screen at six weeks postpartum does not preclude the development of depression at three or six months.
• Item 10 sensitivity concerns. While Item 10 is a valuable safety screen, research suggests that some individuals may not disclose self-harm thoughts on a written questionnaire, particularly in settings where they feel observed or judged. Direct clinical inquiry about suicidal ideation should supplement, not be replaced by, this single item.

The EPDS is most effective when embedded within a stepped-care model — a systematic approach where screening results determine the level and type of follow-up care offered.

Negative screen (score 0–9): Routine care continues with periodic rescreening at subsequent visits. Clinicians should still engage in brief conversations about emotional well-being, as some individuals with depression will score below the cutoff.

Borderline screen (score 10–12): Many guidelines recommend repeating the EPDS in two to four weeks and conducting a brief clinical interview to explore the individual's mood, functioning, and support systems. Psychoeducation about perinatal mood disorders and available resources is appropriate at this stage.

Positive screen (score 13+): A comprehensive clinical evaluation is indicated. This typically involves a structured or semi-structured diagnostic interview, assessment of functional impairment, evaluation of psychosocial risk factors, safety assessment (expanding on Item 10), and consideration of differential diagnoses including anxiety disorders, bipolar disorder, adjustment disorders, and medical conditions such as thyroid dysfunction.

Endorsed self-harm (Item 10 ≥ 1): Immediate safety assessment is required regardless of total score. This includes direct questioning about suicidal ideation, intent, plan, and access to lethal means. Depending on the level of risk, interventions may range from safety planning and crisis resources to emergency psychiatric evaluation.

In practice, the EPDS serves as a conversation starter as much as a numerical score. Many clinicians use the completed questionnaire as a framework for discussing specific concerns — for example, "I notice you indicated you've been feeling anxious quite a lot this week. Can you tell me more about that?" This approach normalizes discussion of perinatal mental health and can reduce stigma.

It is critical that EPDS screening occurs within a system that has clear referral pathways in place. Screening without follow-up is ethically problematic — identifying distress without offering a path to care can increase frustration and erode trust. Clinical settings implementing EPDS screening should have established protocols for mental health referral, crisis intervention, and ongoing monitoring.

The Edinburgh Postnatal Depression Scale is a publicly available instrument that can be used without licensing fees for clinical and research purposes. It is reproduced in full in the original 1987 publication by Cox, Holden, and Sagovsky in the British Journal of Psychiatry.

The scale and its scoring instructions can be accessed through the following sources:

• Original publication: Cox, J.L., Holden, J.M., & Sagovsky, R. (1987). Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150, 782–786.
• Professional organizations: Many obstetric, midwifery, and perinatal mental health organizations provide the EPDS along with administration and interpretation guidelines on their websites.
• Textbook resources: The scale is reproduced in Perinatal Mental Health: The Edinburgh Postnatal Depression Scale Manual (2nd edition) by Cox, Holden, and Pearkopf (2014), which provides comprehensive guidance on administration, scoring, and clinical use.
• Translated versions: Validated translations in dozens of languages are available through published research articles and organizations such as the International Marce Society for Perinatal Mental Health.

Clinicians and organizations are generally free to reproduce the EPDS for clinical use, though they should verify that they are using a properly validated version and follow the original scoring instructions exactly. Modifying item wording, response options, or scoring methodology can compromise the tool's psychometric properties.

If you or someone you know is experiencing persistent sadness, anxiety, difficulty bonding with a baby, loss of interest in previously enjoyable activities, feelings of guilt or worthlessness, or thoughts of self-harm during pregnancy or the postpartum period, seeking professional evaluation is strongly encouraged. These experiences are common — perinatal depression affects an estimated 10–20% of birthing individuals — and they are treatable.

A healthcare provider can conduct a thorough evaluation, which may include the EPDS along with other assessment methods, to determine whether patterns are consistent with perinatal depression or another condition and to develop an appropriate care plan.

If you are having thoughts of harming yourself or your baby, this is a mental health emergency. Contact the 988 Suicide & Crisis Lifeline (call or text 988 in the United States), the Crisis Text Line (text HOME to 741741), the Postpartum Support International HelpLine (1-800-944-4773), or go to your nearest emergency department. You do not need to wait for a screening score to seek help.

Perinatal mood and anxiety disorders are among the most common complications of pregnancy and childbirth. Early identification through tools like the EPDS, combined with appropriate clinical follow-up, significantly improves outcomes for both the parent and the child.